Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Baudax Bio, Inc.BXRX · Entity 109081 | Director | June 15, 2022 | June 17, 2022 |
| INSMED IncINSM · Entity 3174 | Chief Financial Officer | March 01, 2017 | March 03, 2017 |
| Provention Bio, Inc.PRVB · Entity 12101 | Chief Financial Officer | May 12, 2021 | May 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Baudax Bio, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,656 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 39,473 · Balance 41,656 F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.
INSMED Inc
Report date March 01, 2017 · Filed March 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,000 |
Ending reported balance
After 2017-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2017-03-01 · Exercise / conversion · Acquired 20,000 · Balance 25,000 Row 2 · 2017-03-01 · Sale · Disposed 20,000 · Balance 5,000 F1: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.46 to $16.74, inclusive. Row 3 · 2017-03-01 · Exercise / conversion · Acquired 10,000 · Balance 15,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65 · Expires 2022-11-07 | Direct | 74,855 |
Reported balance
After 2017-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-01 · Exercise / conversion · Disposed 20,000 · Balance 74,855 F2: Stock options granted on November 7, 2012 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.65 · Expires 2022-11-07 | Direct | 45,145 |
Reported balance
After 2017-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-01 · Exercise / conversion · Disposed 10,000 · Balance 45,145 F2: Stock options granted on November 7, 2012 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.46 to $16.74, inclusive.
F2: Stock options granted on November 7, 2012 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Provention Bio, Inc.
Report date May 12, 2021 · Filed May 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2031-05-12 | Direct | 139,500 |
Reported balance
After 2021-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-12 · Grant · Acquired 139,500 · Balance 139,500 F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1: 69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: 69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024.
F2: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2022 Filed Jun 17, 2022 16:12 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 39,473 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-015128 · form4.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,656 F1 · shares: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 19:37 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantStock Option (right to buy) · Derivative | 139,500 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001493152-21-011577 · ownership.xml · derivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,500 Underlying: Common Stock, par value $0.0001 · 139,500 shares Expires 2031-05-12 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 69,750 of the options granted will vest as follows: 25% will vest and become exercisable on May 12, 2022 and 75% will vest and become exercisable monthly over 36 months such that these options will be fully vested and exercisable on May 12, 2025. The remaining 69,750 of the options granted will vest and become exercisable, if at all, in three equal installments of 23,250 options, with each such installment triggered upon the achievement of one of three separate corporate performance milestones prior to or during the year 2024. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 19:11 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantStock Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001192482-21-000330 · edgar.xml · derivative · entry 2 Drechsler Andrew T · CIK 0001324734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,333 Underlying: Common Stock · 83,333 shares Expires 2031-04-07 F2 · derivative.exercise_date: The stock option will vest on April 7, 2022. Read SEC document |
| April 07, 2021 Filed Apr 8, 2021 19:11 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 56,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000330 · edgar.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,452 F1 · shares: All shares of common stock are represented by unvested restricted stock units that will vest on April 7, 2022. Vested shares will be delivered to the reporting person within 30 days following the vesting date. Read SEC document |
| September 02, 2020 Filed Sep 2, 2020 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 2,000 | $11.72 | $23,440.00 |
DisclosureSEC source: 0001493152-20-017159 · ownership.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.71 to $11.73, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 16:20 UTC | Baudax Bio, Inc. BXRX · Entity 109081 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000691 · edgar.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: All of the shares of common stock are represented by restricted stock units that will vest 50% on each of August 20, 2021 and August 20, 2022, subject to continued service through the applicable vesting date. Read SEC document |
| August 13, 2020 Filed Aug 13, 2020 19:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock | 1,750 | $13.01 | $22,767.50 |
DisclosureSEC source: 0001493152-20-015601 · ownership.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.02, inclusive. The reporting person undertakes to provide to Provention Bio, Inc., any security holder of Provention Bio, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 18:01 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 137,750 | $0.00 Strike: $12.62 | $0.00 |
DisclosureSEC source: 0001493152-20-013471 · ownership.xml · derivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,750 Underlying: Common Stock, par value $0.0001 · 137,750 shares Expires 2030-07-15 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 55,100 option shares vest in four equal annual installments commencing on July 15, 2021; the remaining 82,650 options shares vest upon completion of certain performance milestones. The completion of each milestone vests 15% of the total option shares. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 17:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | GrantOption (right to buy) · Derivative | 400,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001493152-19-009703 · ownership.xml · derivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock, par value $0.0001 · 400,000 shares Expires 2029-06-24 F2 · price: The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan. F1 · derivative.exercise_date: 160,000 option shares vest in four equal annual installments commencing on June 24, 2020; the remaining 240,000 options shares vest upon completion of certain performance milestones. The completion of each milestone vests 20% of the total option shares. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 20:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001493152-18-016231 · ownership.xml · derivative · entry 2 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 531,720 Underlying: Common Stock · 10,000 shares Expires 2027-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on September 11, 2017, pursuant to the Issuer's 2017 Equity Incentive Plan. 216,688 option shares vest in four equal annual installments commencing on September 1, 2018; the remaining 325,032 option shares vest upon completion of certain performance milestones. The completion of each milestone vests 15% of the total option shares. Read SEC document |
| November 13, 2018 Filed Nov 14, 2018 20:00 UTC | Provention Bio, Inc. PRVB · Entity 12101 | Exercise / conversionCommon Stock | 10,000 | $2.50 | $25,000.00 |
DisclosureSEC source: 0001493152-18-016231 · ownership.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2018 Filed Jul 19, 2018 17:56 UTC | Provention Bio, Inc. PRVB · Entity 12101 | PurchaseCommon Stock, par value $0.0001 per share | 6,250 | $4.00 | $25,000.00 |
DisclosureSEC source: 0001493152-18-010233 · ownership.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on July 19, 2018. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001127430-17-000017 · edgar.xml · derivative · entry 5 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,145 Underlying: Common Stock · 10,000 shares Expires 2022-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on November 7, 2012 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001127430-17-000017 · edgar.xml · derivative · entry 4 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,855 Underlying: Common Stock · 20,000 shares Expires 2022-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on November 7, 2012 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 10,000 | $6.65 | $66,500.00 |
DisclosureSEC source: 0001127430-17-000017 · edgar.xml · nonDerivative · entry 3 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 20,000 | $16.51 | $330,200.00 |
DisclosureSEC source: 0001127430-17-000017 · edgar.xml · nonDerivative · entry 2 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.46 to $16.74, inclusive. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 20,000 | $6.65 | $133,000.00 |
DisclosureSEC source: 0001127430-17-000017 · edgar.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option · Derivative | 5,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001127430-16-000162 · edgar.xml · derivative · entry 2 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,145 Underlying: Common Stock · 5,000 shares Expires 2022-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Stock options granted under the Company's 2000 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 17, 2016 Filed Nov 18, 2016 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 5,000 | $6.65 | $33,250.00 |
DisclosureSEC source: 0001127430-16-000162 · edgar.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · derivative · entry 6 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2023-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Stock Options granted under the Company's 2000 Stock Incentive Plan. On March 20, 2013, the Reporting Person was granted an option to purchase 50,000 shares of common stock. The option vests in two equal installments based upon the Company's satisfaction of two separate performance metrics. One such performance metric was met by the Company on February 26, 2015, resulting in vesting of the option as to 25,000 shares. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option · Derivative | 20,000 | $0.00 Strike: $6.65 | $0.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · derivative · entry 5 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,855 Underlying: Common Stock · 20,000 shares Expires 2022-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted under the Company's 2000 Stock Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 25,000 | $14.67 | $366,750.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · nonDerivative · entry 4 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price in column 4 is a weighted average price. The prices actually paid by the Reporting Person in these transactions range from $14.22 to $14.915. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 25,000 | $6.90 | $172,500.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · nonDerivative · entry 3 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 20,000 | $14.67 | $293,400.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · nonDerivative · entry 2 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price in column 4 is a weighted average price. The prices actually paid by the Reporting Person in these transactions range from $14.22 to $14.915. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:07 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 20,000 | $6.65 | $133,000.00 |
DisclosureSEC source: 0001127430-16-000158 · edgar.xml · nonDerivative · entry 1 Drechsler Andrew T · CIK 0001324734 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.